Clinical Trials Sponsored by Altea Therapeutics

Total 6334 results

Altea Therapeutics

Completed

Transdermal Basal Insulin Patch Study in Type 1 Diabetes

Type 1 Diabetes

United States
Altec Inc.

Recruiting

MyoVoice to Restore Natural, Hands-free Communication to Individuals With Vocal Impairments

Speech Disorders | Speech Perception | Rehabilitation of Speech and Language Disorders | Speech, Alaryngeal | Communication Aids for Disabled | Speech Intelligibility

United States
Antea Foundation

Completed

Procedural Pain in Palliative Care: Prevalence, Intensity and Treatment

Pain | Cancer | Breakthrough Pain | Pain Due to Certain Specified Procedures | Terminal Disease

Italy
Altesa Biosciences, Inc.

Enrolling by invitation

Phase 1 Study Into Pharmacokinetics and Food Effect of Vapendavir in Healthy Participants and Participants With COPD

Healthy | Pulmonary Disease | COPD | Respiratory Disease | Lower Respiratory Disease

United States
Alvea Holdings, LLC

Completed

Safety, Tolerability and Immunogenicity of Alveavax-v1.2, a BA.2/Omicron-optimized, DNA Vaccine for COVID-19 Prevention

Sars-CoV-2 Infection

South Africa
Atea Pharmaceuticals, Inc.

Recruiting

A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV

Hepatitis C | Hepatitis C, Chronic | HCV | Chronic Hepatitis C Virus | Hepatic Cirrhosis

Turkey, Brazil, Romania, Canada, Philippines, Pakistan, South Africa, Moldova, Republic of, India, Korea, Republic of, Mauritius
Atea Pharmaceuticals, Inc.

Recruiting

Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function

Hepatic Impairment | Healthy Volunteer

United States
Atea Pharmaceuticals, Inc.

Active, not recruiting

SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19

COVID-19 | SARS CoV 2 Infection

United States, Argentina, Brazil, Canada, Germany, India, Japan, Latvia, Mexico, Netherlands, Pakistan, Philippines, Romania, South Africa, Spain, Sweden, Tunisia, Turkey, United Kingdom
Atea Pharmaceuticals, Inc.

Completed

Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects

Healthy Volunteer Study

Canada
Atea Pharmaceuticals, Inc.

Terminated

Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model

Dengue

United States
Atea Pharmaceuticals, Inc.

Completed

Study of AT-527 in Healthy Subjects Under Fasting Conditions or With a Meal

Healthy Volunteer Study

Canada
Atea Pharmaceuticals, Inc.

Withdrawn

Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects

Hepatitis C Virus Infection | Hepatitis C | Hepatitis C, Chronic | Chronic Hepatitis C | HCV Infection

Belgium
Atea Pharmaceuticals, Inc.

Completed

Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection

Hepatitis C Virus Infection | Hepatitis C | Hepatitis C, Chronic | Chronic Hepatitis C | HCV Infection

Belgium, Mauritius, Moldova, Republic of
Atea Pharmaceuticals, Inc.

Not yet recruiting

Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/Ruzasvir

Healthy Volunteer Study

Canada
Atea Pharmaceuticals, Inc.

Terminated

Study of AT-752 in Patients With Dengue Infection

Dengue Fever

Brazil, Colombia, Ecuador, India, Malaysia, Peru, Philippines, Taiwan, Thailand, Vietnam
Atea Pharmaceuticals, Inc.

Completed

Study of AT-752 in Healthy Subjects

Dengue

Australia
Atea Pharmaceuticals, Inc.

Recruiting

Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir

Healthy Volunteer Study

United States
Atea Pharmaceuticals, Inc.

Recruiting

Study of AT-527 in Subjects With Normal and Impaired Renal Function

Renal Impairment | Healthy Volunteer

Canada
Atea Pharmaceuticals, Inc.

Completed

The Study of Bemnifosbuvir in Healthy Japanese Subjects

Healthy Volunteer Study

United States
Atea Pharmaceuticals, Inc.

Completed

Drug-drug Interaction Study of Ruzasvir and Bemnifosbuvir (AT-527)

Healthy Volunteer Study

Canada
Atea Pharmaceuticals, Inc.

Terminated

Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospital Setting

COVID-19

United States, Argentina, Belgium, Brazil, Egypt, Moldova, Republic of, Romania, South Africa, Spain, Ukraine
Atea Pharmaceuticals, Inc.

Completed

Study of AT-527 in Healthy and HCV-Infected Subjects

Hepatitis C | Hepatitis C, Chronic | Chronic Hepatitis C

Belgium, Moldova, Republic of
Altec Inc.
Columbia University

Completed

Precision Gait Retraining for Children With Cerebral Palsy

Cerebral Palsy | Gait Disorders, Neurologic

United States
University of Cruz Alta

Unknown

Effects of Bariatric Surgery on Inspiratory Metaboreflex in Obese Subjects

Obesity | Metabolic Syndrome

Brazil
Altec Inc.
Madonna Rehabilitation Hospital

Completed

Adaptive and Individualized AAC

Communication Disorders

United States
Renske Altena

Terminated

Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer (PREDIXIIHER2)

HER2-positive Breast Cancer | Early-stage Breast Cancer

Sweden
Cancer Research UK
Aleta BioTherapeutics

Recruiting

A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies

Lymphoma, Follicular | Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin | Lymphoma, Mantle-Cell

United Kingdom
Altec Inc.
University of Nebraska

Not yet recruiting

Adaptive and Individualized AAC Phase II

Communication Disorders
Antea Foundation
Abbott Diabetes Care

Active, not recruiting

GLYPALCARE STUDY - Multicenter, Randomized Study for Evaluating Continuous Glucose Monitoring (CGM) by Using FreeStyle Libre 2 (FSL2) for Preventing Hyperglycemia/Hypoglycemia Crisis in Advanced Oncological Patients.

Diabetes Mellitus, Type 2 | Diabetes | Cancer | Diabetes Mellitus, Type 1 | Advanced Cancer | Palliative Care | Terminal Illness | End Stage Cancer | Terminal Cancer

Israel, Italy, Switzerland
Alta Bates Summit Medical Center

Unknown

Acupuncture for the Treatment of Chronic Post-Chemotherapy Fatigue

Fatigue

United States
Alta Bates Summit Medical Center

Not yet recruiting

Ketamine for MS Fatigue

Multiple Sclerosis

United States
Alta Bates Summit Medical Center

Terminated

GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors (GSM)

Urinary Tract Infections | Breast Cancer Female | Dyspareunia | Dysuria | Genitourinary Abnormality | Vaginal Abnormality

United States
Altesa Biosciences, Inc.
Virtus Respiratory Research

Recruiting

RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection

Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases | Lung Diseases | Pulmonary Disease, Chronic Obstructive | Enterovirus Infections | Copd | Pulmonary Disease | Respiratory Disease | Respiratory Complication | Upper Respiratory Tract Infections | Respiratory Viral Infection | ... and other conditions

United Kingdom
Ranok Therapeutics (Hangzhou) Co., Ltd.

Recruiting

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

Advanced Solid Tumor | DLBCL

United States
Hoffmann-La Roche
Atea Pharmaceuticals, Inc.

Terminated

Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19 (MORNINGSKY)

COVID-19

Switzerland, Turkey, Denmark, Belgium, Japan, Mexico, Argentina, Brazil, Germany, Portugal, Romania, Ukraine
Atea Pharmaceuticals, Inc.
Hoffmann-La Roche

Completed

Drug-drug Interaction Study of Rosuvastatin and AT-527 (R07496998)

Healthy Volunteer Study

Canada
Atea Pharmaceuticals, Inc.
Hoffmann-La Roche

Completed

Bronchopulmonary PK of AT-527 (R07496998)

Healthy Volunteer Study

United Kingdom
Atea Pharmaceuticals, Inc.
Hoffmann-La Roche

Completed

Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998)

Healthy Volunteer Study

United States
Hoffmann-La Roche
Atea Pharmaceuticals, Inc.

Terminated

A Six-Month Follow-Up Study of Participants With Coronavirus Disease 2019 (COVID-19) Previously Enrolled in a RO7496998 (AT-527) Study (MEADOWSPRING)

COVID-19 | Long COVID

Denmark, Switzerland, Turkey, Belgium, Mexico, Brazil, Argentina, Germany, Romania, Ukraine
Hoffmann-La Roche
Atea Pharmaceuticals, Inc.

Completed

Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19

COVID-19

Spain, Canada, United Kingdom, Greece, Ireland, Latvia
Atea Pharmaceuticals, Inc.
Hoffmann-La Roche

Completed

Drug-drug Interaction Study of Digoxin and AT-527 (R07496998)

Healthy Volunteers Study

Canada
Atea Pharmaceuticals, Inc.
Hoffmann-La Roche

Completed

Study of AT-527 in Healthy Subjects (R07496998)

Healthy Volunteer Study

Canada
Atea Pharmaceuticals, Inc.
Hoffmann-La Roche

Completed

Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527

Healthy Volunteer Study

Canada
Atea Pharmaceuticals, Inc.
Hoffmann-La Roche

Completed

Drug-drug Interaction Study of Midazolam and AT-527 (R07496998)

Healthy Volunteer Study

Canada
HNO-Praxis Alte Post
Aerin Medical

Completed

Evaluate the Effectiveness of the Vivaer ARC Stylus for Nasal Breathing

Nasal Obstruction, Bilateral

Germany
Atea Pharmaceuticals, Inc.
Hoffmann-La Roche

Completed

Effect of Cyclosporine on the Pharmacokinetics (PK) of AT-527 (R07496998)

Healthy Volunteer Study

Canada
Hospital Central Sur de Alta Especialidad

Unknown

Multivariate Analysis of Serum High Sensitivity C-Reactive Protein in Patients With Acute Phase Stroke (MAASP)

Stroke | National Institutes of Health Stroke Scale | Serum High Sensitivity C-Reactive Protein

Mexico
Akebia Therapeutics
Cyclerion Therapeutics

Completed

A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria

Type 2 Diabetes Mellitus With Diabetic Nephropathy

United States
Akebia Therapeutics
Cyclerion Therapeutics

Completed

A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) (CAPACITY-HFpEF)

Heart Failure With Preserved Ejection Fraction

United States, Canada
Antea Foundation
Istituto Di Ricerche Farmacologiche Mario Negri

Recruiting

Evaluation of ESMO Guidelines Applicability and Adherence in Cancer Pain Management in the Palliative Care Setting

Pain | Cancer | Cancer Pain

Italy

Clinical Trials Sponsored by Altea Therapeutics

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations